儿童高身材的评估与管理

慕佳霖; 陈志红

doi:10.16766/j.cnki.issn.1674-4152.003262

儿童高身材的评估与管理

doi: 10.16766/j.cnki.issn.1674-4152.003262

慕佳霖,
陈志红^,

青岛大学附属医院儿童内分泌消化科，山东青岛 266000

详细信息

通讯作者:
陈志红，E-mail：chchch96@sina.com

中图分类号: R179
计量
- 文章访问数: 106
- HTML全文浏览量: 44
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-26
- 网络出版日期: 2024-01-13

Evaluation and management of tall stature in children

MU Jialin,
CHEN Zhihong^,

Department of Pediatric Endocrinology Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China

摘要

摘要: 高身材是指身高超过同种族、同年龄、同性别正常儿童平均身高2个标准差或第97百分位；或者身高超出遗传靶身高2个标准差以上。社会对高身材的接受度普遍较高，甚至高身材有明显优越感，因此临床关注度远低于矮身材。与矮身材类似，高身材可以出现在生长过程的各个时期，大多数为良性过程，部分为正常生长模式的变异或内分泌紊乱所致，部分可能是过度生长综合征临床表现之一，并且伴有多种发育异常，甚至罹患肿瘤风险高，需要引起临床医生重视。详细的病史采集、全面查体和相关的辅助检查，对评估儿童高身材原因至关重要。目前国内外无高身材诊治指南和共识，没有统一干预指征和措施，多以降低成年终身高和改善心理焦虑为目标。口服性激素或经皮股骨远端及胫腓骨近端骨骺闭合术是减缓生长的主要治疗措施。本文对儿童高身材的评估与管理作一综述，旨在提高临床医生对于儿童高身材的认识，帮助临床医生及早查明儿童高身材的原因，给予恰当的指导和干预，避免成年终身高受损和过度生长带来的焦虑，特别是降低肿瘤的发生风险。
- 高身材 /
- 评估 /
- 管理 /
- 儿童
Abstract: Tall stature is defined as a height more than two standard deviations (SD) above the mean for the same race, age and sex; or greater than the 97th percentile. It is also defined as the height exceeds the midparental height by more than 2 SD. There has been a high degree of acceptance for tall stature in the society, and people with tall stature even have an obvious sense of superiority. Both of above lead to a far less clinical attention to tall stature than that of short stature. Similar to short stature, tall stature can occur in various periods of growth, and mostly belong to benign process. In some cases, it can be a variation of normal growth pattern or endocrine disorder. Yet in some cases, it can be one of the clinical manifestations of overgrowth syndrome, accompanied by multiple developmental abnormalities and even high risk of cancer. Therefore, the clinician should pay attention to tall stature. Detailed history taking, general examination and relevant ancillary tests are essential to assess the cause of tall stature in children. Currently, relevant research reports in this field are seldom at home and abroad, and there is a lack of intervention indications and measures, mostly aimed at reducing excessive lifetime height and improving psychological anxiety. Oral sex hormones or epiphysiodesis are the main treatments to slow down growth. This paper devotes to make an overall review of the evaluation and management of tall stature in children, to provide appropriate guidance and intervention, to avoid anxiety associated with impaired adult lifetime height and excessive growth, and especially to reduce the risk of tumor development.
- Tall stature /
- Evaluation /
- Management /
- Children

HTML全文

图 1 儿童高身材的诊断评估流程图

Figure 1. Flowchart for the diagnostic assessment of tall stature in children

下载: 全尺寸图片幻灯片

参考文献(37)

[1]	TATSUHIKO U. Tall stature in children and adolescents[J]. Minerva pediatr, 2020, 72(6): 472-483.
[2]	MEAZZA C, GERTOSIO C, GIACCHERO R, et al. Tall stature: a difficult diagnosis?[J]. Ital J Pediatr, 2017, 43(1): 66. doi: 10.1186/s13052-017-0385-5
[3]	WEI C, GREGORY J W. Physiology of normal growth[J]. Paediatr Child Health, 2009, 19(5): 236-240. doi: 10.1016/j.paed.2009.02.007
[4]	中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会儿童保健学组, 中华儿科杂志编辑委员会. 儿童体格发育评估与管理临床实践专家共识[J]. 中华儿科杂志, 2021, 59(3): 169-174. The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association, the Subspecialty Group of Child Health Care, the Society of Pediatrics, Chinese Medical Association, the Editorial Board, Chinese Journal of Pediatrics. Expert consensus on clinical practice of assessment and management of childhood physical development[J]. Chinese Journal of Pediatrics, 2021, 59(3): 169-174.
[5]	ERICK J, MDALAN D. The child with tall stature and/or abnormally rapid growth. UpToDate[EB/OL]. (2020-10-26)[2022-02-11]. https://www.uptodate.com/contents/the-child-with-tall-stature-and-or-abnormally-rapid-growth/print.
[6]	COUTANT R, DONZEAU A, DECREQUY A, et al. How to investigate a child with excessive growth?[J]. Ann Endocrinol(Paris), 2017, 78(2): 98-103. doi: 10.1016/j.ando.2017.04.006
[7]	CORREDOR B, DATTANI M, GERTOSIO C, et al. Tall stature: a challenge for clinicians[J]. Curr Pediatri Rev, 2019, 15(1): 10-21. doi: 10.2174/1573396314666181105092917
[8]	刘冲, 云惠聪, 张秀兰, 等. 内蒙古自治区3~18岁儿童体格发育调查[J]. 中华全科医学, 2022, 20(2): 327-331. doi: 10.16766/j.cnki.issn.1674-4152.002344 LIU C, YUN H C, ZHANG X L, et al. Survey of physical development in children aged 3 to 18 years in Inner Mongolia[J]. Chinese Journal of General Practice, 2022, 20(2): 327-331. doi: 10.16766/j.cnki.issn.1674-4152.002344
[9]	SERRAT M A, MACHNICKI A L, SONG C A, et al. Mechanisms of linear growth acceleration in childhood obesity[J]. The FASEB Journal, 2020. DOI: 10.1096/fasebj.2020.34.s1.00418.
[10]	ASA S L, EZZAT S. An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism[J]. J Clin Med, 2021, 10(11): 2254. DOI: 10.3390/jcm10112254.
[11]	吴洁, 朱丽萍, 吴久玲, 等. 女性性早熟的诊治共识[J]. 中国妇幼健康研究, 2018, 29(2): 135-138. doi: 10.3969/j.issn.1673-5293.2018.02.001 WU J, ZHU L P, WU J L, et al. Consensus on diagnosis and treatment of female precocious puberty[J]. Chinese Journal of Woman and Child Health Research, 2018, 29(2): 135-138. doi: 10.3969/j.issn.1673-5293.2018.02.001
[12]	LANE C, MILNE E, FREETH M. The cognitive profile of Sotos syndrome[J]. J Neuropsychol, 2019, 13(2): 240-252. doi: 10.1111/jnp.12146
[13]	FOSTER A, ZACHARIOU A, LOVEDAY C, et al. The phenotype of Sotos syndrome in adulthood: a review of 44 individuals[J]. Am J Med Genet C Semin Med Genet, 2019, 181(4): 502-508. doi: 10.1002/ajmg.c.31738
[14]	VILLANI A, GREER M, KALISH J M. Recommendations for cancer surveillance in individuals with rasopathies and other rare genetic conditions with increased cancer risk[J]. Clin Cancer Res, 2017, 23(12): e83-e90. doi: 10.1158/1078-0432.CCR-17-0631
[15]	WEAVER D D. Weaver syndrome and EZH2 -Related overgrowth syndromes[M]. 2019: 95-126. DOI: 10.1093/med/9780190944896.003.0005.
[16]	MANOR J, LALANI S R. Corrigendum: overgrowth syndromes—evaluation, diagnosis, and management[J]. Front Pediatr, 2020, 8: 574857. DOI: 10.3389/fped.2020.574857.
[17]	PRIOLO M, SCHANZE D, TATTON-BROWN K, et al. Further delineation of Malan syndrome[J]. Hum Mutat, 2018, 39(9): 1226-1237. DOI: 10.1002/humu.23563.
[18]	BELLUCCO F T, MELLO C, MELONI V A, et al. Malan syndrome in a patient with 19p13.2p13.12 deletion encompassing NFIX and CACNA1A genes: case report and review of the literature[J]. Mol Genet Genomic Med, 2019, 7(12): e997. DOI: 10.1002/mgg3.997.
[19]	吴英, 阮焱, 闫慧慧. 脆性X综合征的发病机制及诊治研究进展[J]. 医学综述, 2018, 24(18): 3664-3668. doi: 10.3969/j.issn.1006-2084.2018.18.025 WU Y, RUAN Y, YAN H H. Research advances in the pathogenesis and diagnosis and treatment of fragile X syndrome[J]. Medical Recapitulate, 2018, 24(18): 3664-3668. doi: 10.3969/j.issn.1006-2084.2018.18.025
[20]	SADIKOVIC B, LEVI M A, KERKHOF J, et al. Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disorders[J]. Genet Med, 2021, 23(6): 1-10.
[21]	GOLABI M, LEUNG A, LOPEZ C. Simpson-Golabi-Behmel syndrome type 1-GeneReviews^Ⓡ-NCBI Bookshelf[J]. Clinical Genetics, 2011, 72(4): 384-386.
[22]	WANG K H, KUPA J, DUFFY K A, et al. Diagnosis and management of Beckwith-Wiedemann syndrome[J]. Front Pediatr, 2020, 7: 562. doi: 10.3389/fped.2019.00562
[23]	CAMMARATA-SCALISI F, AVENDAO A, STOCK F, et al. Beckwith-Wiedemann syndrome: clinical and etiopathogenic aspects of a model genomic imprinting entity[J]. Arch Argent Pediatr, 2018, 116(5): 368-373.
[24]	ALESSANDRO M, CRISTINA M, FLAVIA C, et al. Assisted reproductive techniques and risk of Beckwith-Wiedemann syndrome[J]. Pediatrics, 2017, 140(1): e20164311. DOI: 10.1542/peds.2016-4311.
[25]	BRIOUDE F, TOUTAIN A, GIABICANI E, et al. Overgrowth syndromes-clinical and molecular aspects and tumour risk[J]. Nat Rev Endocrinol, 2019, 15(5): 299-311. doi: 10.1038/s41574-019-0180-z
[26]	KALISH J M, DOROS L, HELMAN L J, et al. Surveillance recommendations for children with overgrowth syndromes and predis position to wilms tumors and hepatoblastoma[J]. ClinCancer Res, 2017, 23(13): e115-e122.
[27]	RADONIC T, DE W P, GROENINK M, et al Critical appraisal of the revised Ghent criteria for diagnosis of Marfan syndrome[J]. Clin Genet, 2011, 80(4): 346-353. doi: 10.1111/j.1399-0004.2011.01646.x
[28]	SAMANGO-SPROUSE C A, COUNTS D R, TRAN S L, et al. Update on the clinical perspectives and care of the child with 47, XXY (Klinefelter Syndrome)[J]. Appl Clin Genet, 2019, 12: 191-202. doi: 10.2147/TACG.S180450
[29]	中华医学会内分泌学分会性腺学组. 克莱恩费尔特综合征诊断治疗的专家共识[J]. 中华内分泌代谢杂志, 2021, 37(2): 94-99. doi: 10.3760/cma.j.cn311282-20201019-00689 Chinese Society of Endocrirdogy Gonadology Group. Expert consensus on diagnosis and therapy of Klinefelter syndrome[J]. Chinese Journal of Endocrinology and Metabolism, 2021, 37(2): 94-99. doi: 10.3760/cma.j.cn311282-20201019-00689
[30]	FAN L J, ZHANG B B, LI L L, et al. Aromatase deficiency: a case series of 46, XX Chinese children and a systematic review of the literature[J]. Clin Endocrinol(Oxf), 2020, 93(6): 687-695. doi: 10.1111/cen.14277
[31]	LORENZ H B, BERNHARD S, EILARD J O, et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene[J]. J Clin Endocrinol Metab, 2002(12): 5476-5484.
[32]	QUAYNOR S D, STRADTMAN E W, KIM H G, et al. Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant[J]. N Engl J Med, 2013, 369(2): 164-171. doi: 10.1056/NEJMoa1303611
[33]	高海涛, 王曦, 许琪, 等. 儿童超重和肥胖与骨龄发育的相关性研究[J]. 中国儿童保健杂志, 2021, 29(7): 767-771. GAO H T, WANG X, XU Q, et al. Correlation of bone age with overweight and obesity in children[J]. Chinese Journal of Child Health Care, 2021, 29(7): 767-771.
[34]	WILLEGGER M, SCHREINER M, KOLB A, et al. Epiphysiodesis for the treatment of tall stature and leg length discrepancy[J]. Wiein Med Wochenschr, 2021, 171(5-6): 133-141. doi: 10.1007/s10354-021-00828-8
[35]	THOMAS R, MIRJAM G, RAINER W, et al. Treatment of tall stature in boys: comparison of two different treatment regimens[J]. Horm res paediatr, 2011, 76(5): 343-347. doi: 10.1159/000332735
[36]	HANNEMA S E, SǍVENDAHL L. The evaluation and management of tall stature[J]. Horm res paediatr, 2016, 85(5): 347-352. doi: 10.1159/000443685
[37]	WILLEGGER M, SCHREINER M, KOLB A, et al. Epiphysiodesis for the treatment of tall stature and leg length discrepancy[J]. Wiein Med Wochenschr, 2021, 171(5-6): 133-141. doi: 10.1007/s10354-021-00828-8